New drug targets Hard-to-Treat cancers after immunotherapy fails

NCT ID NCT04471987

First seen Jan 16, 2026 · Last updated May 16, 2026 · Updated 16 times

Summary

This early-stage study tests a new drug called IL12-L19L19 in people with advanced or spreading solid tumors that no longer respond to standard immunotherapy. The main goal is to find a safe dose and check for early signs that the drug shrinks tumors. About 80 adults aged 18 to 80 will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Azienda Ospedaliero-Universitaria San Luigi Gonzaga

    NOT_YET_RECRUITING

    Orbassano, Italy

    Contact

    Contact

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    RECRUITING

    Milan, 20133, Italy

    Contact

    Contact

  • Geneva University Hospital, Oncology Department

    RECRUITING

    Geneva, Canton of Geneva, 1211, Switzerland

    Contact

    Contact

  • IEO - Istituto Europeo di Oncologia

    RECRUITING

    Milan, Italy, Italy

    Contact

    Contact

  • Insel Gruppe AG

    RECRUITING

    Bern, Canton of Bern, 3010, Switzerland

    Contact

    Contact

  • Oncology Institute of Southern Switzerland

    RECRUITING

    Bellinzona, 6500, Switzerland

    Contact

    Contact

  • Universitaetsklinik Hamburg-Eppendorf

    RECRUITING

    Hamburg, Free and Hanseatic City of Hamburg, Germany

    Contact

    Contact

  • Universitätsklinikum Heidelberg, Nationalen Centrum für Tumorerkrankungen (NCT), Dermatoonkologie

    RECRUITING

    Heidelberg, Heidelberg, 69120, Germany

    Contact

    Contact

  • Universitätsklinikum Leipzig, Klinik für Dermatologie, Venerologie und Allergologie

    RECRUITING

    Leipzig, Leipzig, 04103, Germany

    Contact

    Contact

  • Universitätsklinikum Tübingen, Klinik für Innere Medizin VIII Medizinische Onkologie und Pneumologie

    RECRUITING

    Tübingen, 72076, Germany

    Contact

    Contact

  • Universitätsspital Basel

    RECRUITING

    Basel, Basel, CH-4031, Switzerland

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.